Your session is about to expire
← Back to Search
KER-012 for Pulmonary Arterial Hypertension
Study Summary
This trial tests a new drug to treat Pulmonary Arterial Hypertension in adults. Participants are randomly given drug or placebo to test safety & efficacy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are researchers currently recruiting participants for this experiment?
"That is correct. According to clinicaltrials.gov, this scientific research project was initially posted on October 17th 2023 and has been recently updated on December 4th 2023. The trial seeks 90 individuals from 6 sites for participation in the study."
Has the FDA officially sanctioned Arm 2 (N=20) for public usage?
"Since the trial is in its second phase, and thus lacks evidence for efficacy but has some data showing safety, Arm 2 (N=20) was given a rating of two on our scale."
How many people are currently participating in this research project?
"Affirmative. According to clinicaltrials.gov, this trial initiated on October 17th 2023 and has been actively seeking participants since then. An estimated 90 individuals need to be enrolled across 6 different sites for the study's completion."
In what geographic locations is this research project currently active?
"At the moment, 6 medical centres are open for enrollment. These locations include Camperdown, Albuquerque and Sydney with 3 other spots available to choose from. To minimize travel costs it is important that you pick a clinic close by if you join this trial."
Share this study with friends
Copy Link
Messenger